Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $33.00 Average PT from Brokerages

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $33.00.

Several research analysts have recently issued reports on the company. Piper Sandler started coverage on Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target for the company. HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Jefferies Financial Group began coverage on shares of Avalo Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $23.00 price target on the stock. Stifel Nicolaus started coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and set a $18.00 target price on shares of Avalo Therapeutics in a report on Thursday, March 20th.

Hedge Funds Weigh In On Avalo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AVTX. Tower Research Capital LLC TRC lifted its stake in Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after buying an additional 3,754 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Avalo Therapeutics in the 4th quarter valued at approximately $114,000. Walleye Capital LLC acquired a new position in Avalo Therapeutics in the 4th quarter worth approximately $145,000. Northern Trust Corp acquired a new position in Avalo Therapeutics in the 4th quarter worth approximately $168,000. Finally, Bank of Montreal Can acquired a new stake in Avalo Therapeutics during the 4th quarter valued at $446,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Price Performance

AVTX opened at $4.41 on Friday. The business’s 50 day moving average is $6.84 and its 200-day moving average is $8.66. Avalo Therapeutics has a twelve month low of $4.15 and a twelve month high of $17.49.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.